Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Benefits"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
dewey-ones:"330 - Economics"
dewey-ones:"700 - The arts; fine & decorative arts"
language:"English"
Showing
1
-
17
of
17
Search:
'"Benefits"'
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Pharmacoeconomic review report: Ivabradine hydrochloride (Lancora)
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
2
Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
3
Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
4
Pharmacoeconomic review report: Ivabradine hydrochloride (Lancora)
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
5
Antibiotic impregnated cement for primary hip or knee arthroplasty : a review of the clinical and cost-effectiveness
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
6
Pharmacoeconomic review report: Upadacitinib (Rinvoq) (AbbVie) : indication: for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an ina...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
7
Telehealth for patients with hypertension, coronary artery disease or implantable cardiac devices : a review of the clinical effectiveness, cost-effectiveness and guidelines
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
8
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
9
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
10
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
11
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
12
Pharmacoeconomic review report: Sarilumab (Kevzara)
Published 2017
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
13
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
14
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
15
Sensory rooms for patients with dementia in long-term care : clinical and cost-effectiveness, and guidelines
by
Banerjee, Srabani
,
Ford, Caitlyn
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
16
Pharmacoeconomic review report: Rivaroxaban (Xarelto) (Bayer Inc.) : indication : in combination with 75 mg to 100 mg acetylsalicylic acid (ASA), for the prevention of stroke, myoc...
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
17
Pharmacoeconomic review report: Rivaroxaban (Xarelto) (Bayer Inc.) : indication : in combination with 75 mg to 100 mg acetylsalicylic acid (ASA), for the prevention of stroke, myoc...
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Classification: 330 - Economics
Clear Filter
Classification: 700 - The arts; fine & decorative arts
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
330 - Economics
700 - The arts; fine & decorative arts
610 - Medicine & health
7
140 - Specific philosophical schools
5
363 - Other social problems & services
1
Language
English
Collection
National Center for Biotechnology Information
17
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
4
Banerjee, Srabani
1
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
1
Ford, Caitlyn
1
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=dewey-ones%3A%22330+-+Economics%22&filter%5B%5D=dewey-ones%3A%22700+-+The+arts%3B+fine+%26+decorative+arts%22&filter%5B%5D=language%3A%22English%22&lookfor=%22Benefits%22&type=Subject
Send by Email
×
Loading...